Finanzen von Oncolytics Biotech Inc (ONCY)ONCYOncolytics Biotech Inc

In the context of the broader market, ONCY competes directly with industry leaders such as SEER and COYA. With a market capitalization of $109.21M, it holds a significant position in the sector. When comparing efficiency, ONCY's gross margin of N/A stands against SEER's 98.71% and COYA's 100.00%. Such benchmarking helps identify whether Oncolytics Biotech Inc is trading at a premium or discount relative to its financial performance.

Oncolytics has been experiencing substantial losses, with a net income of -12,679,060.40 CAD in Q1 2026 and a forward P/E of 45.45, indicating high expectations for future earnings despite current losses.